Introduction. The sarcoplasmic reticulum Ca2+ ATPase (SERCA) is essential for the regulation of the intracellular calcium level in cardiomyocytes. Previous studies have found that angiotensin II (Ang II) decreased SERCA2 gene expression in ventricular myocytes. Alteration of SERCA activity is important in the mechanism of atrial fibrillation. The present study was undertaken to examine Ang II effects on atrial myocytes.
Materials and methods. An ~1.75-kb promoter region of SERCA2 gene was cloned with the pGL3 luciferase vector. The direct effects of Ang II on SERCA2 gene expression in HL-1 atrial myocytes were examined by promoter activity assay, followed by Western blot analysis for protein levels and quantitative real-time reverse transcription polymerase chain reaction for mRNA amounts.
Results. Ang II did not increase the promoter activity of the 1,754-bp promoter-receptor construct of the SERCA2 gene. The levels of SERCA2 protein and mRNA were also unchanged at different time points after Ang II treatment.
Conclusions. Although Ang II had prominent effects on SERCA2 in ventricular myocytes, it did not alter SERCA2 gene expression and protein levels in atrial myocytes. We provide a model for further investigation of the regulation of SERCA2 gene expression in atrial myocytes.
Periasamy M. , Huke S.SERCA pump level is a critical determinant of Ca(2+) homeostasis and cardiac contractility. J Mol Cell Cardiol2001;33:1053-63.
2.
Ver Heyen M. , Heymans S., Antoons G. et al. Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res2001;89:838-46.
3.
Brilla CG, Pick R., Tan LB et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res1990;67:1355-64.
4.
Ohkusa T., Ueyama T., Yamada J. et al. Alterations in cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation. J Am Coll Cardiol1999;34:255-63.
5.
Lai LP, Su MJ, Lin JL et al. Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol1999;33:1231-7.
6.
Cao K., Xia X., Shan Q. et al. Changes of sarcoplasmic reticular Ca(2+)-ATPase and IP(3)-I receptor mRNA expression in patients with atrial fibrillation. Chin Med J (Engl)2002;115:664-7.
7.
Ju H., Scammel-La Fleur T., Dixon IMAltered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II. J Mol Cell Cardiol1996 ;28:1119-28.
8.
Flesch M., Schiffer F., Zolk O. et al. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens1997;15:1001-09.
9.
Tsai CT, Wang DL, Chen WP et al. Angiotensin II increases expression of alpha1c subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes. Circ Res2007;100:1476-85.
10.
Claycomb WC , Lanson NA, Jr, Stallworth BS et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A1998;95:2979-84.
11.
Tsai CT, Lai LP, Hwang JJ et al. Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J Hypertens2008;26:570-82.
12.
Xiao HD, Fuchs S., Campbell DJ et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol2004;165:1019-32.
13.
Lijnen P., Petrov V., van Pelt J. et al. Inhibition of superoxide dismutase induces collagen production in cardiac fibroblasts. Am J Hypertens2008 ;21:1129-36.
14.
Zhou J., Xu X., Liu JJ et al. Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes. Clin Exp Pharmacol Physiol2007;34:1191-8.
15.
Trivieri MG , Oudit GY, Sah R. et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci U S A2006 ;103:6043-8.
16.
Lin CC, Lin JL, Lin CS et al. Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation. Chest2004;126:1926-32.
17.
Terentyev D. , Viatchenko-Karpinski S., Gyorke I. et al. Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: mechanism for hereditary arrhythmia. Proc Natl Acad Sci U S A2003;100:11759-64.
18.
He H., Giordano FJ, Hilal-Dandan R. et al. Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest1997;100:380-9.
19.
Ausma J., Dispersyn GD, Duimel H. et al. Changes in ultrastructural calcium distribution in goat atria during atrial fibrillation. J Mol Cell Cardiol2000 ;32:355-64.
20.
Sun H., Chartier D., Leblanc N. et al. Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res2001;49:751-61.
21.
Shinagawa K. , Mitamura H., Ogawa S. et al. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling . Cardiovasc Res2002;54:438-46.
22.
Nakashima H. , Kumagai K., Urata H. et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation2000;101:2612-17.
23.
Ducharme A. , Swedberg K., Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J2006;152:86-92.
24.
Schmieder RE , Kjeldsen SE, Julius S. et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens2008;26:403-11.
25.
Vermes E., Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation2003 ;107:2926-31.
26.
Healey JS, Baranchuk A., Crystal E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol2005;45:1832-9.
27.
Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation2002;106:331-6.
28.
Gassanov N. , Brandt MC, Michels G. et al. Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation. Cell Calcium2006;39:175-86.
29.
Komuro I., Yazaki Y.Control of cardiac gene expression by mechanical stress. Annu Rev Physiol1993;55:55-75.
30.
Villegas S. , Villarreal FJ, Dillmann WHLeukemia inhibitory factor and interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes . Basic Res Cardiol2000;95:47-54.
31.
Shah RD, Gonzales F., Golez E. et al. The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alphainduced IL-6 secretion in ventricular myocytes. Cell Physiol Biochem2005;15:41-50.
32.
Vangheluwe P., Schuermans M., Zador E. et al. Sarcolipin and phospholamban mRNA and protein expression in cardiac and skeletal muscle of different species. Biochem J2005;359:151-9.
